Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick F Smith

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
Clinical Pharmacokinetics|December 10, 2014
Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevirBarbara J Brennan, Agnès Poirier, Sebastian Moreira, et al.
Antimicrobial Agents and Chemotherapy|April 20, 2011
Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infectionCaralee J Schaefer, Karl Kossen, Sharlene R Lim, et al.
Pharmacotherapy|March 1, 2006
Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteersDesiree L Tomilo, Patrick F Smith, Abayomi B Ogundele, et al.
Clinical Pharmacokinetics|May 29, 2013
Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporinBarbara J Brennan, Sebastian A Moreira, Peter N Morcos, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2005
Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhiBrent M Booker, Patrick F Smith, Alan Forrest, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 26, 2006
Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitorsQing Ma, Olanrewaju O Okusanya, Patrick F Smith, et al.
Clinical Pharmacokinetics|January 7, 2005
Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individualsPatrick F Smith, Robert Dicenzo, Alan Forrest, et al.
Clinical and Translational Science|April 15, 2023
Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participantsSibel Ucpinar, Patrick F Smith, Li Long, et al.
British Journal of Clinical Pharmacology|March 8, 2014
Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studiesYa-Chi Chen, Coen Bernaards, Rohit Kulkarni, et al.
British Journal of Clinical Pharmacology|August 19, 2020
Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modelling for dosing regimen optimizationStefan Sturm, Annabelle Lemenuel-Diot, Kashyap Patel, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Clinical Pharmacokinetics|December 10, 2014
Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevirBarbara J Brennan, Agnès Poirier, Sebastian Moreira, et al.
Antimicrobial Agents and Chemotherapy|April 20, 2011
Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infectionCaralee J Schaefer, Karl Kossen, Sharlene R Lim, et al.
Pharmacotherapy|March 1, 2006
Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteersDesiree L Tomilo, Patrick F Smith, Abayomi B Ogundele, et al.
Clinical Pharmacokinetics|May 29, 2013
Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporinBarbara J Brennan, Sebastian A Moreira, Peter N Morcos, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2005
Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhiBrent M Booker, Patrick F Smith, Alan Forrest, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 26, 2006
Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitorsQing Ma, Olanrewaju O Okusanya, Patrick F Smith, et al.
Clinical Pharmacokinetics|January 7, 2005
Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individualsPatrick F Smith, Robert Dicenzo, Alan Forrest, et al.
Clinical and Translational Science|April 15, 2023
Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participantsSibel Ucpinar, Patrick F Smith, Li Long, et al.
British Journal of Clinical Pharmacology|March 8, 2014
Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studiesYa-Chi Chen, Coen Bernaards, Rohit Kulkarni, et al.
British Journal of Clinical Pharmacology|August 19, 2020
Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modelling for dosing regimen optimizationStefan Sturm, Annabelle Lemenuel-Diot, Kashyap Patel, et al.
Pageof 7